the 6 months following the quality assurance intervention were included. Sputum samples were processed at the Texas Department of State and Health Services (DSHS) Laboratory.
Clofazimine for Treatment of Mycobacterium abscessus Infections in Children
Background. Mycobacterium abscessus infections are increasingly common and can be challenging to treat due to antimicrobial resistance. Clofazimine (CFZ), which is commonly used for treatment of leprosy, comes as a 50 mg capsule that must be swallowed whole. It has excellent in vitro activity against M. abscessus but there are limited reports of its use, particularly in children. During a healthcare associated outbreak of M. abscessus odontogenic infections, 27 children were treated with a CFZ containing regimen for several months.
Methods. Data was collected on all children who received CFZ for a proven or probable M. abscessus odontogenic infection via a Food and Drug Administration Investigational New Drug Application. Demographic, diagnostic and therapeutic information was evaluated, as were laboratory results, adverse events and clinical outcomes.
Results. Of 27 children who received CFZ, 13 were male, 22 were Hispanic and mean age at initial dosing was 5.8 years (range 3.0 -9.4 years). Patients also received azithromycin, amikacin and either imipenem or cefoxitin, though the β-lactam was stopped an average of 31 days after CFZ started. All 27 children had osteomyelitis of the jaw and received aggressive surgical debridement; 10 had a positive stain for acid-fast bacilli (AFB) and 14 had a positive AFB culture (13 M. abscessus, 1 M. chelonae) . Lung nodules were present in 16 children and granulomatous lymphadenitis requiring surgery in 10. Patients received a mean of 105.6 total days of CFZ therapy (range 84-164 days) with a mean weekly dose of 7.6 mg/kg and with dosing occurring a mean of 3 days a week. Every child was able to swallow the CFZ capsule. Minor skin discoloration was noted in 6 children, dry skin in 17, and gastrointestinal symptoms in 11. No child had a clinically significant change in corrected QT interval. All children showed evidence of jaw healing and resolution of lymphadenitis at the end of therapy, and 14 had resolved or improving lung nodules.
Conclusion. This is the largest reported case series of children receiving clofazimine for reasons other than leprosy. It is also the largest report of clofazimine use for extra pulmonary M. abscessus infections. Clofazimine appears to be safe in children and may be an effective part of a surgical and multi-drug regimen for M. abscessus infections.
Disclosures. Background. Leprosy Type 1 (T1R) reactions are immune-mediated events leading to nerve damage and preventable disability affecting hands, feet and eyes. TNF-α is the main inflammatory cytokine associated. Type 1 Reactions are treated with oral corticosteroids. There is little evidence on alternative treatments for patients who do not respond to steroids or experience steroid adverse effects. We report the results of a randomized controlled trial testing the efficacy and adverse effect profile of Anti-TNF α Bio-similar Adalimumab and prednisolone in comparison to prednisolone only in patients with new T1R. Outcomes were measured using a clinical severity score, recurrence rate, adverse events and quality of life.
Methods. Seventy-three patients with new T1R were randomized to receive Adalimumab or Prednisolone for 20 weeks. TNF-α levels were corelated before and after the intervention.
Results. Recovery rates in skin signs was similar in both groups (91% vs 88%). Improvements in nerve function both, new and old, sensory (66% vs 49%) and motor (75% vs 74%) loss were higher (but not significantly so) in the patients on Adalimumab. Recurrences rates of T1R (85%) were high in both groups, and recurrences occurred significantly earlier (8 weeks) in patients Adalimumab, who needed 10% more additional prednisolone. Serious major and minor adverse events rates were much lesser with Adalimumab as compared with Prednisolone alone. Both groups had a significant improvement in their quality of life after the study, measured by the Short form survey SF-36.
Conclusion. This is the first double-blind RCT assessing adalimumab, in the management of T1R. It could be a safe alternative second-line drug for patients with T1R who are not improving with prednisolone or are experiencing adverse events related to prednisolone. TNF-α levels could be an important diagnostic marker to diagnose and prognisticate cases of Type 1 Lepra reaction, which if not treated in time can lead to irreversible nerve damage.
Disclosures. All authors: No reported disclosures. October 7, 2017: 12:30 PM Background. Nontuberculous Mycobacteriae (NTM) are widely distributed in natural environments and are known to cause human diseases distinct from tuberculous mycobacteria. NTM caused diseases may lead to significant morbidity and mortality, particularly in immunocompromised hosts such as cancer patients. We present here a 5-year experience of NTM isolates at the Moffitt Cancer Center and research institute in Tampa, Florida.
Nontuberculous Mycobacteria Isolates at a Cancer
Methods. We conducted a single center, retrospective study of patients with NTM from January 2011 to February 2016. Records were searched to identify patients with NTM. Specimens included bronchial lavage, swabs, blood, body fluids and biopsy or excised surgical specimens. Basic demographics of patients, clinical attributes, presentation and sites from which the NTM were isolated and associated neoplastic pathologies were evaluated for each NTM type and compared.
